Skip to main content

Novan, Inc. (NOVN)

NASDAQ: NOVN · IEX Real-Time Price · USD
4.64
-0.33 (-6.64%)
At close: Dec 3, 2021 4:00 PM
4.63
-0.01 (-0.22%)
After-hours:Dec 3, 2021 7:01 PM EST

Company Description

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases.

Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.

The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is based in Durham, North Carolina.

Novan, Inc.
Novan Logo
CountryUnited States
Founded2006
IPO DateSep 21, 2016
IndustryPharmaceuticals
SectorHealth Care
Employees23
CEOPaula Stafford

Contact Details

Address:
4105 Hopson Rd
Morrisville, North Carolina 27560-9018
United States
Phone919 485 8080
Websitenovan.com

Stock Details

Ticker SymbolNOVN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001467154

Key Executives

NamePosition
Paula Brown Stafford M.P.H.President, Chief Executive Officer and Chairwoman
John M. Gay CPAChief Financial Officer and Corporate Secretary
Andrew J. NovakVice President of Accounting and Business Operations and Chief Accounting Officer
Dr. Carri Geer Ph.D.Senior Vice President and Chief Technology Officer
Cole IkkalaDirector of Investor Relations, Communications and Business Development
Stanley Hollenbach BS,J.D.Senior Vice President of Research & Development
Brian M. JohnsonChief Commercial Officer
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.Chief Medical Officer
Elizabeth MessersmithSenior Vice President and Chief Development Officer

Latest SEC Filings

DateTypeTitle
Nov 30, 20218-KCurrent report
Nov 12, 20214Statement of changes in beneficial ownership of securities
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 9, 20218-KCurrent report
Sep 9, 20218-KCurrent report
Aug 12, 2021S-8Securities to be offered to employees in employee benefit plans
Aug 12, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 12, 20218-KCurrent report
Jun 24, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Jun 21, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings